Neurizon Therapeutics (ASX:NUZ)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neurizon Therapeutics (ASX:NUZ) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Neurizon Invites Investors to Melbourne Briefing
Change of Director's Interest Notice
Proposed issue of securities - NUZ
Notification of cessation of securities - NUZ
New NUZ-001 Mechanistic Data Presented at BIO 2026
Application for quotation of securities - NUZ
Neurizon executes long-term supply agreement with Elanco
Neurizon secures five-year supply agreement with Elanco to advance NUZ-001 commercialisation
HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Neurizon surpasses 50% dosing milestone in HEALEY ALS Platform Trial ahead of schedule
Application for quotation of securities - NUZ
Webinar presentation - Regimen I expands to 240 participants
HEALEY ALS Trial Regimen I Expands to 240 Participants
Neurizon expands HEALEY ALS trial cohort to 240 participants with accelerated timeline and stable costs
Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
Neurizon Gets Ethics Approval for Phase 1 NUZ-001 Oral Liquid ALS Study
Final Director's Interest Notice
Initial Director's Interest Notice
Australian Microcap Investment Conference Presentation
Neurizon Strengthens Board for the Next Growth Phase
Change of Director's Interest Notices
Neurizon investor briefing presentation
Application for quotation of securities - NUZ
Appendix 4C & Quarterly Update
Section 708A Cleansing Statement
Application for quotation of securities - NUZ
Neurizon Investor Briefings Invitation
Placement of Entitlement Offer Shortfall
Neurizon raises A$2.7M via placement of entitlement offer shortfall to support NUZ-001 development
